Loading organizations...
3H Health Investment is a private equity and venture capital firm based in Hong Kong with an additional branch in Shanghai, focusing on early-stage, growth, and expansion opportunities within the healthcare and life sciences sectors. The firm provides capital and strategic support to companies developing medical innovations, biopharmaceuticals, and healthcare technologies. Operating through a team of four primary investment decision-makers, the organization currently manages three distinct private equity funds. The firm's investment portfolio and historical transaction involvement feature prominent pharmaceutical and medical technology companies, including CSPC, Simcere, and Consun. Additionally, the firm's leadership has been involved in significant industry transactions, such as the acquisition of Dihon by Bayer AG. 3H Health Investment was founded in July 2016 by Managing Partner Mr. Wang alongside other founding partners.
Key people at 3H Health Investment.
The firm concentrates on biotechnology and pharmaceuticals, as well as medical technology, with a focus on underlying technology platforms and key sectors.
3H Health Investment maintains operational bases in both Hong Kong and Shanghai.
The firm concentrates on biotechnology and pharmaceuticals, as well as medical technology, with a focus on underlying technology platforms and key sectors.
3H Health Investment maintains operational bases in both Hong Kong and Shanghai.
Key people at 3H Health Investment.
3H Health Investment has 7 tracked investments across 4 companies. The latest tracked deal is $130.0M Series D in Angitia Biopharmaceuticals in February 2026.
